Samarth Kulkarni sold $616k of CRSP
Chief Executive Officer at CRISPR Therapeutics AG. 14,435 shares at an average of $42.70, traded Mar 11, 2025, filed Mar 12, 2025.
Score components
- +25RoleCEO
- +20Trade size$616k at market
- 0Share of holdings soldSold 7.6% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-038216, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | MOption exercise Common Shares | +19,250 | - | - | 190,863 | Mar 12, 2025 |
| Mar 11, 2025 | SOpen-market sale Common Shares | -9,973 | $42.42 | $423k | 180,890 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Common Shares | +9,000 | - | - | 189,890 | Mar 12, 2025 |
| Mar 12, 2025 | SOpen-market sale Common Shares | -4,462 | $43.32 | $193k | 185,428 | Mar 12, 2025 |
| Mar 10, 2025 | MOption exercise Restricted Stock Unitsderivative | -19,250 | - | - | 38,500 | Mar 12, 2025 |
| Mar 11, 2025 | MOption exercise Restricted Stock Unitsderivative | -9,000 | - | - | 0 | Mar 12, 2025 |
Related signals
Other insiders at CRISPR Therapeutics AG and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $119k 1,990 shares | -2% | |
| 8Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $626k 10,400 shares | -10% | |
| 40Moderate | CRISPR Therapeutics AG | Ali Behbahani director | $781k 13,679 shares | -45% | |
| 32Weak | CRSPsell CRISPR Therapeutics AG | Samarth Kulkarni Chief Executive Officer | $761k 13,081 shares | -6% | |
| 54Moderate | CRSPbuy CRISPR Therapeutics AG | Douglas A Treco director | $1.1M 20,000 shares | +1000% | |
| 50Moderate | CRSPbuy CRISPR Therapeutics AG | Simeon George director | $51M 989,812 shares | +1567% | |
| 21Weak | CRSPsell CRISPR Therapeutics AG | Naimish Patel Chief Medical Officer | $141k 3,932 shares | -39% | |
| 33Weak | CRISPR Therapeutics AG | Julianne Bruno Chief Operating Officer | $71k 1,714 shares | -14% | |
| 26Weak | CRISPR Therapeutics AG | James R. Kasinger General Counsel and Secretary | $131k 3,185 shares | -4% | |
| 36Weak | CRISPR Therapeutics AG | Raju Prasad Chief Financial Officer | $91k 2,197 shares | -12% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.